Novo Nordisk is reducing the out-of-pocket costs of its common weight-loss drug Wegovy and diabetes drug Ozempic for some shoppers.
Present clients who pay for the medication out of pocket — with out the assistance of medical insurance — will now be charged $349 per 30 days, down from $499, the Danish drugmaker stated Monday.
Novo Nordisk additionally introduced that it’s going to cost $199 per 30 days for brand new sufferers who pay for the medication out of pocket, with the provide protecting two months of the therapies. After that, the price of the medication will rise to $349 per 30 days. The introductory $199 provide will likely be accessible by means of March 31, 2026, it stated.
The brand new pricing for individuals who pay out of pocket for the 2 common medication comes amid a push from the Trump administration to decrease their costs. In a deal introduced earlier this month, the administration stated individuals who depend on Medicare, Medicaid and the deliberate “TrumpRx” pharmaceutical web site will get decrease pricing for Novo Nordisk’s GLP-1 medication, in addition to Eli Lilly’s Zepbound.
On the time, administration officers stated the medication would price a mean of $245 to $350, a extra accessible value level given they’ll retail for greater than $1,000 per 30 days.
Dave Moore, government vp of U.S. operations of Novo Nordisk, advised CBS Information in a press release that the corporate’s new provide is meant to develop entry to medicines for sufferers dwelling with continual illnesses.
“Novo Nordisk is making it simpler and extra inexpensive for sufferers to entry actual FDA-approved therapies,” he stated.
Prospects can get prescriptions on the new costs at wegovy.com or ozempic.com, at NovoCare Pharmacy or by means of different choose suppliers resembling Costco.
